Updates in Treg Mediation in Parkinson's?

The article I reviewed, Neuroprotective activities of CD4+CD25+ regulatory T cells inan animal model of Parkinson’s disease, identified Tregs as a potent modulator of microglial activity in MPTP mice, the animal model for Parkinson’s disease. In the conclusion, the author states that the “importance of the observations in the present study rests with the idea that they can be readily translated to the clinic,” noting the recently discovered mechanisms of Tregs in the disease as potential areas for clinical manipulation. However, as noted in class, we are not able to simply inject Tcells into Parkinson’s patients. I have looked for information regarding the use of Tregs in neurodegenerative diseases, primarily Parkinson’s disease, since the study was published in 2007. Cell death of dopamine secreting cells is the primary problem in Parkinson’s, and as such, the primary treatment is still dopamine supplementation rather than inhibition of cellular death. Sources like Google Health, Web MD and Mayo Clinic, which provide information to the general public, do not even mention the inflammatory regulation of the disease, indicating that influencing concentrations of T regulatory cells has yet to become a viable option for treatment, despite the articles assertions that the study could be “readily translated to the clinic.” Furthermore, I have had difficulty locating follow up studies regarding the induction of T regulatory immune responses in neurodegenerative diseases. I would be interested to know if anyone has heard of further developments in these studies, or if the article was simply overenthusiastic in its belief that studies could translate to human trials.